Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan

Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan

Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is effective in treating patients with non-small cell lung cancer (NSCLC) after unsuccessful chemotherapy. However, survival outcomes and predictors for its effectiveness in chemotherapy-naive NSCLC patients are still...

Full description

Bibliographic Details
Main Authors:	Cheng-Ta Yang, Jen-Yu Hung, Chun-Liang Lai, Hsin-Chia Hung, Yung-Fa Lai, Meng-Chih Lin, Jiunn-Min Shieh, Ming-Shyang Huang
Format:	Article
Language:	English
Published:	Wiley 2010-01-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	gefitinib non-small cell lung cancer target therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S1607551X10700012

Similar Items

Analysis of Prognostic Factors of 80 Advanced NSCLC Patients Treated with Gefitinib for more than 6 Months
by: Ling DAI, et al.
Published: (2010-11-01)

Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung
by: Mark H. Cooper
Published: (2018-01-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

Clinical Observation of Gefitinib with Pericardial Perfusion for  Advanced Non-small Cell Lung Cancer
by: Xiaomeng WANG, et al.
Published: (2018-01-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
by: Xiao Ling Ni, et al.
Published: (2017-01-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
by: Zhang L, et al.
Published: (2021-05-01)

Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1
by: Gang JIA, et al.
Published: (2008-06-01)

Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases
by: Jianping XU, et al.
Published: (2015-09-01)

A rare case of synchronous multiple primary lung cancer with different responses to gefitinib
by: Che-Chi Liao, et al.
Published: (2020-01-01)

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
by: Ibrahim Ezzeldin
Published: (2010-01-01)

Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
by: Zhixue Fu, et al.
Published: (2020-06-01)

The combination astemizole–gefitinib as a potential therapy for human lung cancer
by: Chávez-López MDG, et al.
Published: (2017-12-01)

Screening and Identification of MicroRNAs Related to Acquired Gefitinib-resistance  in Lung Adenocarcinoma Cell Lines
by: Xuebo QIN, et al.
Published: (2011-06-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
by: Lin L, et al.
Published: (2016-10-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma
by: Datong CHU, et al.
Published: (2008-02-01)

Massive pleural effusion and associated pulmonary embolism in a case of Gefitinib responsive lung cancer
by: Rajiv Garg, et al.
Published: (2015-01-01)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
by: Hong Yang, et al.
Published: (2021-11-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
by: Wang Huiyu, et al.
Published: (2019-12-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01)

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
by: Thomas K. Sin, et al.
Published: (2016-02-01)

Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo
by: Xiaoxia Zhao, et al.
Published: (2021-04-01)

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
by: Wenxiong Zhang, et al.
Published: (2018-08-01)

Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells
by: Tingting YANG, et al.
Published: (2018-06-01)

Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma
by: Sian Yik Lim, et al.
Published: (2011-04-01)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
by: Fabrizio Gozzi, et al.
Published: (2021-04-01)

The Mechanism of Gefitinib Resistance Induced by Hepatocyte Growth Factor  in Sensitive Non-small Cell Lung Cancer Cells in Vitro
by: Xianglan XUAN, et al.
Published: (2013-01-01)

Classification and Regression Tree Analysis of Clinical Patterns that Predict Survival in 127 Chinese Patients with Advanced Non-small Cell Lung Cancer Treated by Gefitinib Who Failed to Previous Chemotherapy
by: Ziping WANG, et al.
Published: (2011-09-01)

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
by: Haibo Cheng, et al.
Published: (2018-11-01)

FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer
by: Cong PENG, et al.
Published: (2021-08-01)

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)